- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00769990
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Phase I-II Trial of Genistein in Subjects Receiving Palliative External Beam Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life
RATIONALE: Genistein may increase the effectiveness of radiation therapy in treating pain caused by bone metastases.
PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in treating patients undergoing external-beam radiation therapy for pain caused by bone metastases.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
- To determine whether genistein is safe when administered in combination with palliative external beam radiotherapy in patients with osseous metastases.
- To determine the time to pain relief, duration of pain relief, and degree of pain relief in patients treated with this regimen.
- To determine the incidence of pathologic fractures in patients treated with this regimen.
- To determine the effect of this regimen on quality of life measures in these patients.
OUTLINE: This is a multicenter study.
Patients undergo external beam radiotherapy once daily on days 1-10. Patients also receive oral genistein once daily on days 1-60.
Patients complete pain and quality-of-life questionnaires periodically.
After completion of study therapy, patients are followed at 30 days.
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed malignant solid tumor, including any of the following:
- Breast cancer
- Lung cancer
- Kidney cancer
- Melanoma
- Prostate cancer
- Radiographic evidence* of bone metastasis within the past 8 weeks NOTE: *Acceptable studies include plain radiograph, radionuclide bone scan, CT scan, and MRI
Has pain that appears to be related to the radiographically documented metastasis, in the opinion of the treating physician, AND a decision has been made by the responsible clinician that a course of palliative external beam radiotherapy is appropriate treatment
- "Worst pain score" of > 5 on a scale of 10 as scored on the pain assessment questionnaire (BPI) (question #3: 0 = no pain; 10 = worst possible pain) OR taking narcotic medications with an oral morphine equivalent dose of > 60 mg/day
- No painful metastases to the skull, hands, or feet
Eligible treatment sites include any of following:
Weight-bearing sites:
- Pelvis (excluding pubis)
- Femur
- Sacrum and/or sacroiliac joints
- Tibia
Non-weight-bearing sites:
- Up to 5 consecutive cervical, thoracic, or lumbar vertebral bodies
- Lumbosacral spine
- Up to 3 consecutive ribs
- Humerus
- Fibula
- Radius ± ulna
- Clavicle
- Sternum
- Scapula
- Pubis
If multiple osseous sites are treated, the treatment site is included as weight-bearing if any of the sites include the pelvis, sacrum, femur, or tibia
- Treatment of multiple osseous sites allowed only if those sites can be included in ≤ 3 treatment sites
- Patients with painful metastases that are contiguous but do not fit into the definition of a site listed above are eligible but are considered to have 2 treatment sites
- No vertebral metastases with clinical or radiographic evidence of spinal cord or cauda equina compression/effacement
- No primary hematologic malignancies (e.g., lymphoma)
Hormone receptor status (for patients with breast cancer):
- Estrogen receptor-negative tumor
- Menopausal status not specified
- Karnofsky performance status 40-100%
- Life expectancy ≥ 3 months
- ALT normal
- Bilirubin normal
- Serum creatinine normal (≤ 1.8 mg/dL for males and ≤ 1.5 mg/dL for females)
- Free T4 and thyroid-stimulating hormone normal
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No pathologic fracture or impending fracture of the treatment site
- No history of primary hyperparathyroidism
- No malabsorptive disease or chronic diarrhea
- No history of sarcoidosis or tuberculosis
Exclusion Criteria:
- Less than 30 days since prior systemic radioisotopes for pain, including Strontium-90 (^90Sr) or Samarium (^153Sm)
- Less than 30 days since prior antibiotics
- Less than 30 days since prior initiation of systemic therapy (e.g., hormonal therapy, chemotherapy, or immunotherapy)
Less than 90 days since prior intravenous bisphosphonate therapy
- Concurrent oral bisphosphonates allowed
- Prior radiotherapy or palliative surgery to the painful sites
- Concurrent surgical fixation of the bone
- Concurrent treatment to the skull, hands, or feet
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Genistein
Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
|
Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
Other Names:
A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: At completion of first 6 patients
|
Frequency of severe (grade 3) toxicities
|
At completion of first 6 patients
|
Secondary Outcome Measures
Outcome Measure |
---|
Time to pain relief, duration of pain relief, and degree of pain relief
|
Incidence of pathologic fractures
|
Effect of treatment on quality of life measures as assessed by the BPI and FACT-G
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shalamar Sibley, MD, MPH, Masonic Cancer Center, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- stage IV renal cell cancer
- recurrent renal cell cancer
- stage IV breast cancer
- recurrent breast cancer
- recurrent non-small cell lung cancer
- extensive stage small cell lung cancer
- recurrent small cell lung cancer
- stage IV prostate cancer
- recurrent prostate cancer
- stage IV non-small cell lung cancer
- pain
- bone metastases
- recurrent melanoma
- stage IV melanoma
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Genital Neoplasms, Male
- Breast Diseases
- Prostatic Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplastic Processes
- Neuroendocrine Tumors
- Nevi and Melanomas
- Kidney Neoplasms
- Breast Neoplasms
- Prostatic Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Melanoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Estrogens, Non-Steroidal
- Estrogens
- Protein Kinase Inhibitors
- Anticarcinogenic Agents
- Phytoestrogens
- Genistein
Other Study ID Numbers
- 2008LS035
- UMN-0803M29541 (Other Identifier: IRB, University of Minnesota)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on genistein
-
Chung Shan Medical UniversityRecruitingCohort Study | Organ Transplantation | Immunosuppressive AgentsTaiwan
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnProstate CancerUnited States
-
University of MessinaMinistry of Education, Universities and Research, ItalyCompleted
-
Children's Hospital of PhiladelphiaCystic Fibrosis FoundationTerminatedCystic FibrosisUnited States
-
Jonsson Comprehensive Cancer CenterWithdrawnPancreatic CancerUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...National Council of Science and Technology, MexicoCompletedObesity | Metabolic Syndrome
-
New York Medical CollegeJohns Hopkins University; Baylor College of Medicine; University of California... and other collaboratorsRecruitingSickle Cell DiseaseUnited States
-
University of California, DavisCompleted
-
St. Justine's HospitalCompleted
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedProstate CancerUnited States